[18F]GTP1

DRUG5 trials

Conditions

Alzheimer DiseaseAlzheimer Disease (AD)Alzheimer's Disease

Phase 1

Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants

CompletedNCT02640092

Genentech, Inc.Alzheimer's Disease

Start: 2015-12-23End: 2019-06-11Updated: 2019-12-23

A Study of the Biodistribution and Safety of [18F]GTP1 in Healthy Japanese Participants

CompletedNCT04394845

Genentech, Inc.Alzheimer Disease

Start: 2020-08-11End: 2020-10-09Updated: 2021-11-03

Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease

CompletedNCT04566003

Genentech, Inc.Alzheimer Disease (AD)

Start: 2020-10-26End: 2023-06-27Updated: 2023-07-12

Phase 2

A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease

TerminatedNCT03289143

Genentech, Inc.Alzheimer's Disease

Start: 2017-10-04End: 2021-01-15Updated: 2022-03-16

A Study of Semorinemab in Patients With Moderate Alzheimer's Disease

CompletedNCT03828747

Genentech, Inc.Alzheimer's Disease

Start: 2019-01-25End: 2023-08-30Updated: 2024-09-24

2026-01-01

Cerebrospinal fluid MTBR243 tau correlates with [18F] GTP1 Tau PET and the two biomarkers show similar correlations with clinical measures

Alzheimer s & Dementia2025-12-01

Development and validation of speech‐based biomarkers for measuring clinical progression in AD clinical trials

Alzheimer s & Dementia2025-12-01

Formal and Informal Care Utilization in Mild Cognitive Impairment and Mild Dementia due to Alzheimer's Disease: Cross-Sectional and Longitudinal Analyses of RUD-Lite Data from the Tauriel Study.

2025-11-25

The Alzheimer's Disease Cooperative Study - Activities of Daily Living dependence score: revision and validation of an algorithm evaluating patient dependence across the spectrum of AD severity.

2025-07-01

Robustness and generalizability of a speech‐based digital biomarker derived from recordings of the Clinical Dementia Rating (CDR) interview

Alzheimer s & Dementia2024-12-011 citations

Deriving meaningful within‐patient change thresholds for the ADCS‐ADL in trials of early and mild‐to‐moderate Alzheimer’s disease ‐ a caregiver‐rated, anchor‐based analysis of the Tauriel and Lauriet trials

Alzheimer s & Dementia2024-12-01

Impact of Study Partner Type on Participant Retention Across Global Regions in the Tauriel and Lauriet Trials for Alzheimer’s Disease

Alzheimer s & Dementia2024-12-01

Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology

Alzheimer s & Dementia2024-11-089 citations

Care partner‐informed meaningful change thresholds for the Clinical Dementia Rating‐Sum of Boxes for trials of early Alzheimer's disease

Alzheimer s & Dementia2024-07-179 citations

Evaluation of partial volume correction and analysis of longitudinal [18F]GTP1 tau PET imaging in Alzheimer's disease using linear mixed-effects models

Frontiers in Neuroimaging2024-03-281 citations

Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease.

2024-02-2216 citations

18F GTP1 Tau PET image‐derived features improve the prediction of CDR‐SB progression in a multi‐modal model in prodromal to moderate AD

Alzheimer s & Dementia2023-12-01

Formal and informal healthcare utilization in MCI and mild dementia due to AD: Cross‐sectional and longitudinal analyses of RUD‐Lite data from the Tauriel Study

Alzheimer s & Dementia2023-12-01

Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet

Neurology2023-08-2994 citations

Cross‐sectional and longitudinal assessments of function in prodromal‐to‐mild Alzheimer's disease: A comparison of the ADCS‐ADL and A‐IADL‐Q scales

Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring2023-04-0110 citations

Evaluation of Longitudinal [18F]GTP1 Tau Burden Metrics in the Tauriel Phase II Study

Alzheimer s & Dementia2022-12-01

Selecting appropriate meaningful change thresholds for trials of early (prodromal‐to‐mild) AD: A caregiver‐rated, anchor‐based analysis based on the Tauriel Study

Alzheimer s & Dementia2022-12-01

Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease

JAMA Neurology2022-06-13171 citations

Baseline [<sup>18</sup>F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer's disease.

2021-12-0120 citations

5 more papers not shown

[18F]GTP1

Sponsors

Conditions

Phase 1

Phase 2

Related Papers